Georgia Bio to Present Lifetime Achievement Award Posthumously to Lee Herron

Georgia Bio, the state’s life science trade association, will honor the late Lee Herron, an industry leader and long-time supporter of Georgia Bio, with its Lifetime Achievement Award at next week’s Georgia Life Sciences Summit which celebrates the contributions and achievements of Georgia leaders who have been instrumental in advancing the growth of the life sciences industry and elevating Georgia’s overall ecosystem. In its 35-year history, Georgia Bio has only ever presented five Lifetime Achievement awards.

 

Lee, who will long be remembered as a pillar and irreplaceable leader in the industry, retired from the Georgia Research Alliance (GRA) in the spring of 2024 after a 16-year career with the Alliance, most recently, Lee led GRA’s agricultural technology programs including the Greater Yield initiative. He directed its award-winning venture development program for 15 years, which helped to launch 200+ university-based companies that attracted more than $2 billion in equity investment. A seasoned executive, Lee harnessed his 20 years of entrepreneurial experience to help startups develop sound business strategies. Lee served in many community leadership capacities, including board positions for Georgia Bio and Southeast Life Sciences, the Global Center for Medical Innovation’s Industry Advisory Board, the Biolocity Oversight Committee, and the NSF Center for Cell Manufacturing Technology’s Commercialization Advisory Board.


“Lee was a true visionary whose passion and integrity touched everyone he met," says Georgia Bio President and CEO, Maria Thacker-Goethe. “His unwavering commitment to innovation and his profound impact on the life sciences industry will be felt for generations to come. We are honored to present him with this award posthumously.”


“The Georgia Research Alliance would not be what it is today without Lee Herron,” says GRA President and CEO Tim Denning, PhD. “Lee helped shape our program that moves university inventions to the marketplace — a program that he led and grew for 16 years. Countless technologies are at work in the world today, benefiting companies and consumers alike, because of Lee’s wisdom, guidance, and desire to make a difference.”


Prior to joining GRA, Lee managed the biosciences division of Georgia Tech’s Advanced Technology Development Center (ATDC) and founded four biosciences companies: SeaLite Sciences Inc., Biopool International Inc., CytRx Corporation, and Theragenics Corporation. Herron received a Doctor of Veterinary Medicine degree from the University of Georgia and completed an internship at Cornell University. He also studied experimental pathology at Emory University.


Lee passed away on July 12, 2024, after a long battle with cancer. He was a devout family man, husband to Rita Herron for 50 years, father to three children, and grandfather to eight children. He leaves behind a profound legacy and will be remembered by his friends and colleagues as a dear friend.


Award Presentation   


Georgia Bio will honor Lee at the opening reception for the organization’s largest annual gathering, the Georgia Life Sciences Summit, taking place on October 21 at the Sandy Springs Performing Arts Center from 5:00pm to 7:00pm.


# # #


About Georgia Bio



Georgia Bio (GaBio) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For over 30 years, GaBio has served its members by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in biotechnology, pharmaceuticals, and medical technology. GaBio also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. GaBio works to shape public policy, improve access to breakthrough technologies, educate lawmakers, provide member programs, strengthens the workforce pipeline, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. For more information, visit www.gabio.org.

 

MEDIA CONTACT:

Melissa Carter

404-920-2043

mcarter@gabio.org

Legal Experts Signal Continued Uncertainty for Life Sciences M&A

By Maria Thacker Goethe • October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape

Georgia Life Sciences Launches New Podcast Series, Vitals, in Partnership with Cloudcast Media

October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.

BIO Statement on Most Favored Nation Policies

October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS